Auxogyn looks to revolutionize IVF

04/10/2014 | San Francisco Chronicle (free content)

Auxogyn recently announced a deal awarding Merck rights to market in Europe and Canada a novel test designed to improve the efficiency and outcomes of in vitro fertilization. The test, known as Eeva, allowed embryologists who used it to identify embryos that were nonviable 86% of the time, compared with 58% of the time without the test, the company said. And company CEO and President Lissa Goldenstein says Auxogyn will continue to advance the technology, which is under regulatory consideration in the U.S.

View Full Article in:

San Francisco Chronicle (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX